News

After a Type A meeting with the FDA regarding oral paclitaxel/encequidar in metastatic breast cancer, Athenex, Inc. has announced that they will be deploying their resources to other avenues of research.

Atezolizumab is the first immunotherapy approved in the adjuvant setting to treat NSCLC.

“Previously, this mutation has been undruggable, but this is now changing.”

The Oncology Nurse Practitioner Fellowship at Sylvester Comprehensive Cancer Center exposes fellows to the gamut of oncology care and teaches the skills they need to succeed.

Pembrolizumab is approved both in combination with chemotherapy, with or without bevacizumab, and as a single agent for the treatment of patients with recurrent or metastatic cervical cancer.

Abemaciclib is the first and only FDA approved CDK4/6 inhibitor to treat HR-positive, HER2-negative high-risk early breast cancer.

Autologous hematopoietic stem-cell transplantation, the standard frontline treatment in treating patients with mantel cell lymphoma, demonstrated superior long-term efficacy compared with interferon alfa in a recent trial.

An expert on pain management discusses safe and effective opioid prescriptions to manage cancer-related pain.

“Although information and persuasion worked for many and incentives worked for a few, we still have a huge number of Americans unvaccinated" - Arthur Caplan, PhD, Drs William F. and Virginia Connolly Mitty Professor of Bioethics, NYU Grossman School of Medicine.

An expert from The University of Texas MD Anderson Cancer Center recently highlighted the ramifications of the phase 2 ReDOS trial, the need for molecular profiling in mCRC, and ongoing research on the combination of TKIs and checkpoint inhibitors.

Although cancer clinical trial enrollment plummeted during the initial wave of the COVID-19 pandemic, study results show that enrollment has rebounded over the past year.

Nursing students sometimes face surprising hostility from nurse preceptors, explains contributor, Serenity Mirabito. However, the best nurse preceptors operate as agents for good by training and fostering the enthusiasm of young nursing students.

Anticipating these stressors and implementing specific strategies can help ease the distress and vulnerability felt by children and adolescents.

Deidra Hamilton, MSN, RN, OCN, ONN-CG, recently presented on how cancer institutions can clearly define the role of a nurse navigator to prevent scope creep and use gap analysis and metrics to showcase the value of a navigator in their program.

Answering questions without judgement and showcasing community members who have received the COVID-19 vaccine without negative outcomes can help alleiviate vaccine-related fears and concerns in BIPOC patients with cancer.

New research suggests that fertility-sparing surgery is feasible and safe in treating ovarian malignant germ cell tumors.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News co-editor in chief, comments on the dedication she has observed from caregivers taking care of loved ones with leukemia during the COVID-19 era.

The Pfizer-BioNTech COVID-19 vaccine induces similar levels of COVID-19 antibodies in patients with solid cancer compared with people without cancer.

Kristin Barber, FNP-BC, AOCNP, discusses ongoing phase 1 trials aimed at targeting mutations along the MAP kinase pathway.

Brexucabtagene autoleucel is now an FDA approved treatment options for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

A new retrospective cohort found that women who had received the human papillomavirus vaccine had similar rates of primary ovarian insufficiency as unvaccinated women.

Loop electrical excision procedure (LEEP) demonstrated superior capabilities in clearing high-risk HPV infections in women with cervical intraepithelial neoplasia (CIN2+).

“When you’re donning that gown to go into a room, you’re donning exactly what that patient needs you to be.”

“I think the biggest [change] that we’ve seen is the addition of adjuvant or consolidated chemotherapy following the completion of concurrent chemotherapy and radiation. We have seen the 4-year overall survival data now and the 5-year update from the PACIFIC study in the adjuvant setting, obviously confirming the initial signal that patients who have initiation of immunotherapy early carry a significant risk reduction for progression and overall survival…”

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, Oncology Nursing News Co-Editor in Chief, shares her opinion on recent developments in leukemia treatment options.

An oncology nurse with over 20 years of experience ponders the necessity of professional privacy in the workplace -particularly in light of COVID-19 vaccinations.

A recent study demonstrated that patients with prostate cancer on active surveillance reported reduced PSA levels after a 12-week HIIT regime.

Cetuximab represents the first approved anti-EGFR antibody which, in combination with encorafenib, is now available to treat adults with pretreated metastatic CRC with a BRAF V600E mutation.